CNS Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
CNS Pharmaceuticals, Inc. (CNSP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $193.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-31
- CNS Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $193.00K.
- CNS Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was -$585.00K, a 595.76% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was $118.00K.
- CNS Pharmaceuticals, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was -$194.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $193.00K 10-K · filed 2026-03-31 | |
| 2024-12-31 | -$585.00K 10-K · filed 2026-03-31 | |
| 2023-12-31 | $118.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | -$194.00K 10-K · filed 2024-04-01 | |
| 2021-12-31 | -$100.00K 10-K · filed 2023-03-31 | |
| 2020-12-31 | -$70.00K 10-K · filed 2022-03-03 | -$227.00K 10-K · filed 2021-02-12 |
| 2019-12-31 | -$83.00K 10-K · filed 2021-02-12 | -$83.40K 10-K · filed 2020-03-12 |
| 2018-12-31 | -$1.37M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |